HeartBeam, Inc. Q1 FY2024 earnings call

Branislav Vajdic introduced HeartBeam's VCG technology, emphasizing its superiority over common personal ECG technologies. The AIMIGo system is an easy-to-use 12-lead ECG solution. Rob Eno provided updates on AIMIGo's progress, including the 510(k) application under review by the FDA, with expectations of FDA clearance by the end of Q2 2024 and a limited launch by the end of 2024. The valid ECG study was enrolling patients, with over 50% enrolled and expected to complete enrollment in Q2 2024. HeartBeam's AI program had acquired 1 million 12-lead ECGs, with deep learning algorithms presented at conferences, demonstrating potential in arrhythmia detection.

For the first quarter ended March 31, 2024, general and administrative expenses were $2.4 million, compared to $2.5 million in the first quarter of 2023. Research and development expenses were $2.4 million, versus $1.7 million in the prior-year period. The net loss was $4.6 million, up from $4.1 million in Q1 2023. Cash and cash equivalents totaled $12.6 million as of March 31, 2024, down from $16.2 million as of December 31, 2023. Net cash used in operations was $3.5 million for the three months ended March 31, 2024.

Anticipate AIMIGo to receive FDA clearance by the end of Q2 2024. Plan to have a limited launch of AIMIGo by the end of 2024. The valid ECG study is expected to complete enrollment in Q2 2024, and the second 510(k) application is planned to be submitted by Q3 2024.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. There is uncertainty regarding the timing of FDA clearance and potential delays in the regulatory process.

Q: Could you remind us what exactly was your go-to-market strategy?

A: Rob Eno mentioned they are targeting the patient pay segment and other market segments, refining the strategy, and will enter a beta testing phase upon clearance, exploring partnerships.

Q: What is the timing of the FDA clearance?

A: Branislav Vajdic expects clearance within the Q2 of 2024.

Q: What is the latest on the valid ECG study?

A: Rob Eno stated all five sites are up and running, enrolling patients, more than 50% enrolled, expected to finish enrollment in Q2.

Q: Can you explain the significance of focusing on atrial flutter in your AI update?

A: Branislav Vajdic said atrial flutter is an important arrhythmia, and their clinical data shows VECG and AI can excellently identify it, differentiating from other conditions.